Compared with existing PD‐L1 antibodies or small‐molecule inhibitors, PTPR peptides regulate PD‐L1 protein levels by targeting TMUB1‐PD‐L1 interactions, potentially circumventing tolerance issues caused by PD‐L1 translocation in conventional ICB therapy.[14] The fluorination modification strategy used in this study improved the lysosomal release of the peptides and preserved their biological activity within the complex tumor microenvironment. The gene discussed is PTPRR; the disease is neoplasm.